Previous close | 25.44 |
Open | 25.15 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 25.12 - 25.74 |
52-week range | 25.12 - 25.74 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces agreement with Janssen to develop immune-based therapies 26.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT Hamburg, Germany, 26 January 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a str
EQS-News: Evotec SE / Key word(s): Quarter ResultsEvotec SE reports results for the first nine months 2022 and provides corporate update 09.11.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY COMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTER Hamburg, Germany, 09 November 2022:Evotec SE (Frankfurt Stock Exchange:
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE to announce results for the first nine months 2022 on 09 November 2022 03.11.2022 / 11:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 03 November 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.The Company is going to hold a conference call to dis